Welcome to the Winter edition of European Ophthalmic Review. This edition, expertly introduced by Andrzej Grzybowski, features timely and concise review articles, editorial and reports across a wide range of topics. Nikki and Farhad Hafezi discuss the best cross-linking procedure in 2016 and May Griffith and colleagues review cornea regeneration as an alternative to human donor transplantation.Baruch Kuppermann analyses the real-word results around the efficacy of ocriplasmin in the treatment of vitreomacular adhesion/traction and Richard Gale and Reema Gupta discuss the best neovascular agre-related macular degeneration regimens for 2016. Also included are a selection of symposium reports from the key meetings of 2015 in the areas of dry eye disease, glaucoma and retinal imaging. We hope this new collection of articles provide useful information relevant to your practice and interests.
Foreword – European Ophthalmic Review, 2016;9(2):97
Awarm welcome to the winter edition of the European Ophthalmic Review. This issue features two papers exploring corneal collagen cross-linking (CXL), in particular, the modifications to the original ‘Dresden protocol’. The two main modifications are transepithelial (epi-on) CXL and accelerated CXL, which seem to rely on a final common pathway that determines efficacy, i.e. oxygen […]
Cataract and Cornea
Will Enhanced Depth-of-focus Intraocular Lenses Lead the Future in Premium Lenses?
Presbyopia normally develops as a person ages and is associated with a natural progressive loss of accommodation ability to rapidly and easily refocus on objects at varying distances. A variety of technologies have been developed to enhance the ability of the intraocular lens (IOL) to facilitate viewing. Multifocal (MF) IOLs were designed to eliminate the […]
Treatment of Corneal Astigmatism at the Time of Cataract Surgery, What Can Be Promised
Cataract surgery offers the ophthalmic surgeon an opportunity to treat corneal astigmatism. However, the question remains, what is reasonably possible and what is needed to attain this possibility? As an initial step, the question needs to be asked, how much astigmatism is significant? Employing adaptive optics and bench top studies, it has been shown that […]
Update on Paediatric Refractive Surgery
Subsequent to the first published feasibility study of photorefractive keratectomy (PRK) on treatment of highly anisometropic, myopic and hyoperopic, amblyopia in children by Singh et al. in 1994, a slew of articles on corneal laser refractive and lens-based intraocular surgery for treatment of paediatric refractive amblyopia in select clinical settings have followed.1 Whereas modern refractive […]
Cornea Regeneration as an Alternative to Human Donor Transplantation
The human cornea is the optically clear window of the eye and its main refractive component that focuses light to the retina allowing vision. Thus, the optical transparency of the cornea is critical for optimal vision. Injury or diseases that cause irreversible loss of transparency lead to vision loss and eventually blindness. Globally, it is […]
Corneal Collagen Cross-linking for Keratoconus
Cross-linking (CXL) is a technique originating from the synthetic polymer field that can be used to alter a polymer’s physical and mechanical properties. It was first proposed for corneal use by Theo Seiler from Germany in 1995 and was later applied clinically in 1998.1 A corneal ‘crosslink’ is a bond between natural polymer chains such […]
Changing Paradigms of Treating Severe Keratitis in Dry Eye Disease
Rationale for Anti-inflammatory Treatment in Severe Dry EyeThe Dry Eye Workshop, in 2007, defined dry eye disease (DED) as a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance and tear film instability, with potential damage to the ocular surface.1 The definition adds that: “It is accompanied by […]
The Challenge of Glaucoma Surgery in the Cataract Patient – Where Are We Now?
Of the approximately 3 million cataract surgeries performed in the US each year, epidemiologists predict that 10 % will have ocular hypertension or open angle glaucoma (OAG). Ophthalmologists must be ready to handle those surgeries as well as the 100,000 stand-alone glaucoma procedures. Glaucoma patients present special challenges in cataract surgery. How you proceed with […]
Trends and Discrepancies in Glaucoma Medical Therapy in Europe
Glaucoma is the second leading cause of blindness in the world, affecting around 65 million people worldwide.1 It has been calculated that 76 million people by 2020 and 112 million people by 2040 will be affected and will require medical care for this progressive optic neuropathy. Very well-defined guidelines have been issued by the European […]
The Vitreoretinal Interface in Retinal Vein Occlusions – A Clue for Surgery?
Retinal vein occlusions (RVO) affect over 16 million people worldwide, with 2.5 million affected by central retinal vein occlusions (CRVO) and 13.9 million affected by branch retinal vein occlusions (BRVO).1 RVO are still the second leading retinal vasculopathy after diabetic retinopathy and the fifth leading cause of monocular blindness.2 Up to 15 % of patients […]
Ocriplasmin Efficacy – An Analysis of Real-World Results From 2013 to 2015
The vitreoretinal interface is a complex structure that facilitates the attachment between the internal limiting membrane of the retina and the vitreous, a clear gel filling the posterior of the eye.1,2 As the eye ages, a series of physiological events occurs to the vitreous, including liquefaction, which predisposes the eye to posterior vitreous detachment (PVD).2 […]
Optical Coherence Tomography Angiography of the Retinal Microvasculature using the Zeiss AngioPlex
Optical coherence tomography (OCT) has proved to be a valuable approach to imaging ocular vasculature and is becoming a critical method in precisely diagnosing the type and identifying the location of retinal disease.1–7 Fluorescein angiography (FA), used to examine the retinal microvasculature, to date has produced valuable diagnostic information and insights into the pathophysiology of […]
What Is the Best Neovascular Age-related Macular Degeneration Treatment Regime for 2016?
Age-related macular degeneration (AMD) is the leading cause of central visual loss and legal blindness in patients over the age of 65 years.1,2 The exudative or neovascular form of AMD accounts for over 90 % of the cases with severe visual loss.3 AMD is a highly complex disease with demographic, environmental and genetic risk factors. […]
Intraocular Telescopic Implants for Age-related Macular Degeneration Eyes
Optical treatment for improving vision of patients that suffer from agerelated macular degeneration (AMD) is not new, but it is still the only option to improve vision for the majority of AMD patients (90 % of AMD are dry-type patients and many of the wet type patients after being treated with injections). Traditionally, external telescopes […]
Diabetic Retinopathy Screening Methods and Programmes Adopted in Different Parts of the World – Further Insights
We recently published a review of diabetic retinopathy (DR) screening methods and programmes adopted in different parts of the world.1 After publication we learnt about more DR screening programmes and believed that this important information should be supplemented with data from Portugal, Denmark and the US (see Table 1). PortugalRibeiro et al.2 presented a study […]
US Ophthalmic Review Highlights
Small Incision Lenticule Extraction (SMILE) in 2015
Ever since femtosecond lasers were first introduced into refractive surgery, the ultimate goal has been to create an intrastromal lenticule that can then be removed in one piece manually, thereby circumventing the need for incremental photoablation by an excimer laser. This was achieved in 2005, presented at the American Academy of Ophthalmology (AAO) meeting in […]
A Novel Avastin Injection Technique—“Sunalp Protocol”
In 2006, the US Food and Drug Administration (FDA) approved Genentech’s ranibizumab (Lucentis®), a Fab fragment of a humanized monoclonal antivascular endothelial growth factor (VEGF)-A designed for intraocular use for the treatment of exudative age-related macular degeneration (ARMD). Since 2006, ranibizumab and its parent monoclonal antibody bevacizumab have been extensively used to treat exudative ARMD. […]
Journal articles and more to your inbox
Get the latest clinical insights from touchOPHTHALMOLOGYSign me up!